decisionhealth Newsletters, Part B News - 2025 Issue 3 (March)
Compounded GLP-1s set to exit market, ending your ability to prescribe
Subscribe or sign in to view the full article.
Article Overview
This article explains recent FDA actions affecting compounded GLP-1 drugs and why the market for these products is changing. It is relevant to clinicians, prescribers, pharmacists, compliance staff, and health care attorneys who need to understand the timing of shortage-related changes, the general framework for compounding under federal law, and the patient communication issues that may follow.
Why This Topic Matters
It helps readers track an FDA-related shift that affects access, prescribing authority, and compliance exposure for compounded versions of widely used GLP-1 medications.
Article Sections
-
Compliance
Overview of the FDA shortage-related context affecting compounded GLP-1 products and the broader compliance implications for providers and compounders.
-
Farewell, online knockoffs
Discussion of the end of shortage-based compounding, the legal framework for compounders, and the timing of market exit for different types of compounders.
-
Tell your patients
General guidance on patient communication, informed consent considerations, and the risks associated with continued access to nontraditional online sources.
What You Will Learn
- How FDA shortage decisions affect compounded drug availability
- What federal compounding authority is discussed in relation to GLP-1 products
- Why the article flags patient counseling and documentation concerns
- Which types of providers and organizations may be affected by the market change
Who Should Read This
- Physicians and other prescribers
- Pharmacists and compounders
- Compliance professionals
- Health care attorneys
- Practice managers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com